Latest Observability News

Connected Minerals Ltd has reported outstanding high-grade uranium results from its extended trenching and sampling program at the Etango North-East Project in Namibia, revealing multiple promising prospects and setting the stage for imminent drilling.

Fortescue Ltd has crossed the 75% ownership threshold in Red Hawk Mining, prompting an increase in its takeover offer price from A$1.05 to A$1.20 per share ahead of the March 3 closing date.

Neurizon Therapeutics has been granted a pivotal US patent for its lead drug candidate NUZ-001, extending protection until 2039 and enhancing its commercial and clinical positioning in neurodegenerative disease treatment.

Apollo Minerals has launched Phase 2 drilling at its Salanie Gold Project in Gabon, building on strong 2024 results that revealed high-grade gold mineralisation and visible gold. The program targets extensions at A1 and new prospects A2, A3, and P6.

A new peer-reviewed study highlights Cynata Therapeutics’ Cymerus™ iPSC-derived MSCs as superior to traditional donor tissue-derived MSCs in potency, consistency, and regenerative potential.

Strickland Metals has reported multiple high-grade gold intercepts from its Gradina Prospect in Serbia, confirming extensive mineralisation and paving the way for a maiden Mineral Resource Estimate later this year.

Meteoric Resources reports exceptional rare earth element grades and enriched magnetic rare earth oxides at its Agostinho Prospect in Brazil, signaling a potential expansion of its Caldeira Project resource base.

Argenica Therapeutics reports compelling preclinical evidence that ARG-007 significantly reduces brain cell damage and neuroinflammation in moderate traumatic brain injury, reinforcing its potential as a breakthrough neuroprotective therapy.

Argenica Therapeutics has reported compelling preclinical data showing ARG-007 significantly reduces brain cell damage and inflammation in moderate traumatic brain injury, matching levels seen in uninjured controls. This reinforces ARG-007’s potential as a breakthrough neuroprotective therapy.

Sigma Healthcare has received Federal Court approval for its acquisition of Chemist Warehouse, marking a pivotal step in its strategic expansion. The scheme is set to become legally effective on February 4, 2025, with implementation expected by February 12.

Alpha HPA Limited has announced key leadership changes, appointing Rob Williamson as Managing Director to steer the company through its next growth phase, while Rimas Kairaitis shifts focus to commercial strategy. The retirement of long-serving director Peter Nightingale marks the end of an era.

Alterity Therapeutics has raised over A$2 million through its U.S. ATM facility and expects nearly A$5.7 million in Australian tax rebates, fueling the advancement of its lead neurodegenerative drug candidate ATH434 following promising Phase 2 results.